Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7501 - 7525 of 8030 in total
SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
Matched Description: … and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of
SR-9011 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
Matched Description: … and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of
Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)).
Investigational
Matched Description: … Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir …
Inavolisib (GDC-0077) is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).
Investigational
Matched Description: … investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of
Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)).
Investigational
Matched Description: … investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of
FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer activity. FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome).
Investigational
Matched Description: … [A257306] FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in …
SS1(dsFv)-PE38 is a recombinant anti-mesothelin immunotoxin. SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-small Cell Lung Adenocarcinoma).
Investigational
Matched Description: … SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 …
XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.
Investigational
Matched Description: … XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual …
SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
Investigational
Matched Description: … It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary …
EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Investigational
Matched Description: … EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being …
S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Investigational
Matched Description: … S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and …
Methyl undecenoyl leucinate is an active ingredient in whitening creams. It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.
Experimental
Matched Description: … an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of
Nequinate is an antiprotozoan used as a coccidiostat for poultry and rabbits. Nequinate belongs to the family of Hydroquinolones. These are compounds containing an hydrogenated quinoline bearing a ketone group.
Vet approved
Matched Description: … Nequinate belongs to the family of Hydroquinolones. …
2-chloroethyl-3-sarcosinamide-1-nitrosourea has been used in trials studying the treatment of Colorectal Cancer, Brain and Central Nervous System Tumors, and Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … 2-chloroethyl-3-sarcosinamide-1-nitrosourea has been used in trials studying the treatment of Colorectal …
Rivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal impairment, Anemia, Sickle Cell, Sickle Cell Disease, and Sickle Cell Disorders, among others.
Investigational
Matched Description: … Rivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal …
LGD-6972 is under investigation in clinical trial NCT01919684 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus).
Investigational
Matched Description: … clinical trial NCT01919684 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of
Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).
Investigational
Matched Description: … investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of
NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).
Investigational
Matched Description: … NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis …
ABT-639 is under investigation in clinical trial NCT01345045 (A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain).
Investigational
Matched Description: … investigation in clinical trial NCT01345045 (A Multicenter Study Comparing the Analgesic Effects and Safety of
Mibenratide is under investigation in clinical trial NCT01798745 (A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies).
Investigational
Matched Description: … investigation in clinical trial NCT01798745 (A Study to Assess the Pharmacokinetics and Pharmacodynamics of
PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms on Donepezil).
Investigational
Matched Description: … 05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of
Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)).
Investigational
Matched Description: … Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A …
Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing peptides. It is under investigation for the treatment of hyperphenylalaninemia.
Investigational
Matched Description: … [L48151] It is under investigation for the treatment of hyperphenylalaninemia. …
YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
Investigational
Matched Description: … YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid …
CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This is a novel therapeutic approach to treat kidney inflammation.
Investigational
Matched Description: … CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived …
Displaying drugs 7501 - 7525 of 8030 in total